OpenEvidence, An AI-Powered ‘Brain Extender’ For Doctors, Doubles Valuation To $12B With $250M Series D

Why It Matters

The valuation jump signals strong market confidence in AI‑driven clinical decision tools, potentially reshaping how physicians access evidence and accelerating AI health‑tech adoption.

Key Takeaways

• Series D raised $250M, valuation $12B.
• Revenue hit $100M annually, free ad-supported model.
• 40% of US physicians use platform daily.
• Consultations grew from 3M to 18M per month.
• AI health funding up 63% YoY in 2025.

Pulse Analysis

OpenEvidence positions itself as a “brain extender,” delivering citation‑linked answers from the latest medical literature directly to clinicians’ screens. By aggregating peer‑reviewed studies, guidelines, and trial data, the platform reduces the time physicians spend hunting for evidence—a task that traditionally consumes up to nine hours a day. Its free, ad‑supported model removes cost barriers for individual doctors while generating revenue through targeted healthcare advertising. This approach contrasts with subscription‑heavy analytics tools, allowing rapid penetration across more than 10,000 hospitals and medical centers in the United States.

The $250 million Series D, which lifted OpenEvidence’s valuation to $12 billion, reflects a broader surge of capital into AI‑enabled health technologies. Investors poured an estimated $14 billion into the sector in 2025, a 63 % increase over the previous year, driven by the promise of cost reduction and improved diagnostic accuracy. Major players such as OpenAI and Anthropic are now adding health modules to their large‑language models, intensifying competition but also validating the market’s appetite for AI‑driven clinical support. OpenEvidence’s $100 million annual revenue demonstrates that a freemium, ad‑backed model can scale profitably alongside venture backing.

For physicians, the platform’s daily usage by over 40 % of U.S. doctors translates into faster access to up‑to‑date evidence, potentially narrowing the gap between research and bedside care. The reported jump from three million to 18 million monthly consultations suggests that clinicians are increasingly relying on AI to validate treatment decisions. As regulatory frameworks for medical AI mature, OpenEvidence’s emphasis on citation transparency may give it a compliance edge. In the long run, widespread adoption could improve patient outcomes, lower malpractice risk, and set a new standard for evidence‑based practice across the healthcare ecosystem.